A US court ruling finds reporting of many clinical trials of unapproved drugs in breach of the law. But responses to the ruling are uncertain.
Less than half of trials on clinicaltrials.gov meet the FDAAA results reporting deadline in a study from Ben Goldacre’s EBM DataLab at Oxford University
[VIDEO] Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment
Gemma Rogers, Communications Director at Oxford Pharmagenesis, discusses a study on clinical trial transparency.
Researchers argue that lay review will increase the relevance of medical publications: a new study aims to evaluate its impact.
A study reported in the New England Journal of Medicine in March found that “despite ethical mandates, statutory obligations, and considerable societal pressure, most trials that were funded by the … Continue Reading Further improvements needed: reporting of results on ClinicalTrials.gov